Development of dendritic cell-based genetic vaccines for cancer

Advances in Experimental Medicine and Biology

Volumn 417, Issue , 1997, Pages 511-518

  Tuting T ^a   Zorina, T ^a   Ma, D I ^a   Wilson, C C ^a   De Cesare, C M ^a   De Leo, A B ^a   Lotze, M T ^a   Storkus, W J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE INSERTION; GENE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ANIMALIA;

EID: 0030870429     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9966-8_84     Document Type: Conference Paper

References (38)

1. Kast, W. M. et al. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-607 (1989)
2. Rosenberg, S.A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma : preliminary report. N. Engl. J. Med. 319, 1676-1680 (1988).
3. Van den Eynde, B., & Brichard, V.G. New tumor antigens recognized by T cells. Current Opinion in Immunology 7, 674-68 (1995).
4. Boon, T., & Van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996).
5. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
6. Stingl, G., & Bergstresser, P. R. Dendritic cells: a major story unfolds. Immunol. Today 16, 330-333 (1995).
7. Inaba, K., Steinman, R.M., Witmer-Pack, M., Aya, H., Inaba, M., Sudo, T., Wolpe, S., & Schuler, G. Identification of proliferating dendritic cell precursors in mouse blood. J. Exp. Med. 175, 157-1167 (1992).
8. Inaba, K., Inaba, M., Romani. N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony-stimulating factor. J. Exp. Med. 176, 693-1702 (1992).
9. Caux, C., Dezutter-Damboyant, C., Schmitt, D., & Bancherau, J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261 (1992).
10. Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Gritsch, P.O., Steinman, R.M., & Schuler. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
11. Szabolcs, P., Moore, M.A. S., & Young, J.W. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J. Immunol. 154, 5851-5861 (1995).
12. Mayordomo, J.I., Zorina, T., Storkus, W.J., Celuzzi, C.M., Falo, L.D., Kast, W.M., Ildstad, S.T., DeLeo, A.B., & Lotze, M.T. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. 1, 1297-1302 (1995).
13. Ossevoort, M.A, Feltkamp, M.C.W., van Veen, K.J.H., Melief, C.J.M., & Kast, W.M. Dendritic cells as carriers for a cytotoxic T lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. 18, 86-94 (1995).
14. Celluzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., & Falo, L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-387 (1996).
15. Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322 (1996).
16. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., & Storkus, W.J. Therapy of murine tumors with tumor peptide pulsed dendritic cells : dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
17. Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, S.M., Appasamy, P. M., Lotze, M.T., Storkus, W.J., Appella, E., & DeLeo, A.B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357-1365 (1996).
18. Porgador, A., Snyder, D., & Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918-2926 (1996).
19. Bakker, A.B.H., Marland, G., de Boer, A.J., Huijbens, J.F., Danen, E.H.J., Adema, G.J., & Figdor, D.G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55, 5330-5334 (1995).
20. van Elsas, A., van der Burg, S.H., van der Minne, C.E., Borghi, M., Mourer, J.S., Melief, C.J.M., & Schrier, P.I. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26, 1683-1689 (1996).
21. Tjandrawan, T., Mäurer, M..J., Castelli, C., Lotze, M.T., & Storkus, W.J. Autologous dendritic cells pulsed with synthetic melanoma peptides elicit specific CTL effector cells in vitro. Manuscript submitted.
22. Conry, R.M., LoBuglio, Loechel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L., & Curiel, D.T. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2, 59-66 (1995).
23. D.M., & Wu, T.-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26 (1996).
24. Ciernik,I.F., Berzofsky, J.A., & Carbone, D. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156, 2369-2375 (1996).
25. Warnier, G., Duffour, M.-T., Uyttenhove, C., Gajewski, T., Lurquin, C., Haddada, H., Perricaudet, M., & Boon, T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer 67, 303-310 (1996).
26. Chen, P.W., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S.A., & Restifo, N.P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 224-231 (1996).
27. Irvine, K.R., Rao, R.B., Rosenberg, S.A., & Restifo, N.P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156, 238-245 (1996).
28. Zhai, Y., Yang, J.C., Kawakami, Y., Spiess, P., Wadsworth, S.C., Cardoza, L.M., Couture, L.A., Smith, A.E., & Rosenberg, S.A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156, 700-710 (1996).
29. Yang, N.-S., Burkholder, J.K., Roberts, B., Martinell, B., and McCabe, D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl. Acad. Sci. USA 87, 9568-9572 (1990).
30. Burkholder, J.K., Decker, J., & Yang, N.-S. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J. Immunol. Methods 165, 149-156 (1993).
31. Yang, N.-S., & Sun, W.-H. Gene gun and other non-viral approaches for cancer gene therapy. Nature Med. 1, 481-483 (1995).
32. Pertmer, T.M., Roberts, T.R., and Haynes, J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. 76:6119-6125 (1996).
33. Feltkamp, M.C.W., Smis, H.L., Vierboom, M.P.M., Minnaar, R.P., de Jongh, B.M., Drijfhout, J.W., ter Schegget, J., Melief, C.J.M., and Kast, W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).
34. Henderson, R.A., Nimgaonkar, M.T., Watkins, S.C., Robbins, P.D., Ball, E.D., and Finn, O.J. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56, 3763-3770 (1996).
35. Ressing, M.E., Sette, A., Brandt, R.M., Ruppert, J., Wentworth, P.A., Hartmann, M., Oseroff, C., Grey, H.M., Melief, C.J.M., and Kast, W.M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:5934-5943 (1995).
36. Houbiers, J.G.A., Nijman, H.W., van der Burg, S.H., Drijfhout, J.W., Kenemans, P., man de Velde, C.J.H., Brand, A., Momburg, F., Kast, W.M., and Melief, C.J.M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072-2077 (1993).
37. Theobald, M., Biggs, J., Dittmer, D., Levine, A., and Sherman, L. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993-11997 (1995).
38. Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Ferson, D.Z,., Hong,W.K., Komari, R., Lee, J.J., Nesbitt, J.C., Pisters, K.M.W., Putnam, J.B., Schea, R., Shin, D.M., Walsh, D.L., Dolormente, M.M., Han, C.-I., Martin, F.D., Yen, N., Xu, K., Stephens, L.C., McDonnell, T.J., Mukhopadhyay, T., and Cai, T. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2:985-991 (1996).